Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesCompass Pathways Plc

Compass Pathways Plc

Healthcare Medical Care Facilities
PortfolioPortfolio WatchlistWatchlist
Company price
8.61 USD 0.80 ( 10.24%)
Last update at 2026-11-06T21:24:00Z
VOLUME
3746701
Market Cap
1917.90M

Momentum Score

…

COMPASS Pathways plc operates as a biotechnology company that focuses on mental health in the United Kingdom and the United States. The company develops COMP360, a psilocybin therapy, which is in Phase III clinical trial for the treatment of treatment-resistant depression; and is in Phase II clinical trial for treating post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. The company was incorporated in 2020 and is headquartered in London, the United Kingdom.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
7.99
Low
8.68
High
52 Week Price Range
4.82
Low
15.87
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Compass Pathways Plc is a clinical-stage mental health company developing COMP360, a proprietary psilocybin therapy for treatment-resistant depression and related psychiatric indications. Long-term growth drivers include clinical development progress, expansion into additional indications and partnerships to scale delivery; investors may find the company attractive because it appears positioned to deliver a novel therapeutic approach to large unmet mental‑health needs.
Primary investment risks are high clinical and regulatory uncertainty, potential safety or efficacy setbacks, commercial and reimbursement challenges, and the likelihood of needing additional financing to complete development and launch.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
7.81
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
0.00M
Debt / Equity
-0.40
ROE
-319.07%
Net Debt
-128.68M
ROCE
478.70%
Diluted EPS TTM
-3.79

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -290.33M -153.53M -117.68M -91.10M -71.54M
Net income -287.86M -155.12M -118.46M -91.50M -71.74M
Selling general administrative 60.60M 59.17M 49.40M 45.35M 39.19M
Selling and marketing expenses - - 0.05M - -
Gross profit -0.22M -0.23M -0.24M - -
Reconciled depreciation 0.22M 0.23M 0.44M 0.33M 0.17M
Ebit -179.25M -149.05M -115.48M -110.40M -83.22M
Ebitda -179.04M -148.82M -115.24M -96.80M -75.56M
Depreciation and amortization 0.22M 0.23M 0.24M 13.60M 7.66M
Non operating income net other - - - - 11.68M
Operating income -179.04M -178.21M -136.92M -110.40M -83.22M
Other operating expenses 179.46M 178.21M 136.92M 95.98M 73.57M
Interest expense 4.53M 4.48M 2.20M 6.03M 4.20M
Tax provision -2.47M 1.59M 0.48M 0.41M 0.20M
Interest income 7.18M 8.27M 4.62M - -
Net interest income 2.67M 3.79M -2.20M - -
Income tax expense -2.47M 1.59M 0.78M 0.41M 0.20M
Total revenue 0.00M 0.00M 0.00M 0.00M 0.00M
Total operating expenses 179.04M 178.21M 136.92M 95.98M 73.57M
Cost of revenue 0.22M 0.23M 0.24M - -
Total other income expense net -111.30M 24.68M 19.23M 19.31M 11.68M
Net income from continuing ops -287.86M -155.12M -116.86M -91.50M -71.74M
Net income applicable to common shares - - - -91.50M -71.74M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 210.35M 213.67M 275.99M 197.29M 300.90M
Other current assets 26.50M 14.39M 11.73M 47.70M 21.62M
Total liab 263.20M 58.97M 50.24M 16.01M 16.49M
Total stockholder equity -52.85M 154.69M 225.74M 181.28M 284.41M
Other current liab 212.94M 14.49M 10.18M 9.32M 0.27M
Common stock 0.97M 0.70M 0.63M 0.44M 0.43M
Capital stock 0.97M 0.70M 0.64M 0.44M 0.43M
Retained earnings -822.59M -534.73M -379.61M -261.15M -169.64M
Other assets - - 0.00M 2.55M 0.98M
Cash 149.61M 165.08M 220.64M 143.21M 273.24M
Total current liabilities 247.79M 34.02M 19.60M 15.60M 15.11M
Current deferred revenue - - 1.12M - 10.04M
Net debt -128.68M -132.89M -187.59M -141.28M -269.63M
Short term debt 19.63M 7.24M 2.41M 1.51M 2.23M
Short long term debt 17.52M 5.51M - - -
Short long term debt total 20.93M 32.19M 33.05M 1.93M 3.61M
Other stockholder equity 783.56M 704.92M 621.64M 458.85M 444.78M
Property plant equipment - - - 2.62M 0.40M
Total current assets 191.49M 201.29M 261.30M 191.65M 295.30M
Long term investments - 0.47M 0.47M 0.47M 0.53M
Net tangible assets - - - 181.28M 284.41M
Net receivables 15.39M 21.82M 28.93M 15.62M 11.22M
Long term debt 14.11M 24.65M 28.76M - -
Inventory - - 0.00M -14.87M -10.78M
Accounts payable 15.22M 12.28M 5.89M 4.76M 2.56M
Accumulated other comprehensive income -14.79M -16.19M -16.93M -16.87M 8.84M
Common stock total equity - - - - 0.46M
Retained earnings total equity - - - - -169.64M
Non currrent assets other 0.73M 5.94M 6.16M 0.33M 0.21M
Non current assets total 18.86M 12.38M 14.69M 5.64M 5.60M
Capital lease obligations 3.40M 2.03M 4.29M 1.93M 3.61M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments - 0.00M -0.17M -0.60M -0.33M
Change to liabilities - - - 0.80M 5.26M
Total cashflows from investing activities - - -0.06M -0.60M -0.33M
Net borrowings - 0.00M 29.59M - -
Total cash from financing activities 140.71M 63.82M 173.83M 1.04M 156.65M
Change to operating activities - - - -31.46M -5.60M
Net income -287.86M -155.12M -118.46M -91.50M -71.74M
Change in cash -15.48M -55.17M 77.26M -129.97M 82.99M
Begin period cash flow 165.47M 220.64M 143.38M 273.35M 190.36M
End period cash flow 149.99M 165.47M 220.64M 143.38M 273.35M
Total cash from operating activities -157.24M -119.19M -97.38M -105.45M -67.75M
Issuance of capital stock 140.36M 26.22M 145.42M 0.44M 154.79M
Depreciation 0.22M 0.23M 0.24M 0.33M 0.17M
Other cashflows from investing activities - - 0.00M - -
Sale purchase of stock - - -0.00M - 156.65M
Other cashflows from financing activities -0.33M 37.60M -0.69M 0.60M 1.85M
Change to netincome - - - 16.39M 7.78M
Capital expenditures 0.00M 0.00M 0.07M 0.60M 0.33M
Cash flows other operating - - - - -9.23M
Cash and cash equivalents changes - - - - 88.57M
Change in working capital -14.28M 11.72M 3.48M -30.67M -6.64M
Stock based compensation 13.59M 19.52M 17.28M 13.12M 8.64M
Other non cash items 131.10M 4.46M 0.09M 3.27M 1.80M
Free cash flow -157.24M -119.19M -97.44M -106.05M -68.08M

Peer Comparison*

Sector: Healthcare Industry: Medical Care Facilities

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to EBITDA (x)
CMPS
Compass Pathways Plc		 0.80
10.24%		 8.61 - - - 22.62 -3.51
HCA
HCA Healthcare, Inc.		 -12.49
2.46%		 494.99 14.27 13.46 1.21 291.34 8.99
THC
Tenet Healthcare Corporation		 -3.13
1.09%		 283.33 10.08 12.66 0.96 4.57 5.80
FSNUY
Fresenius SE & Co KGaA ADR		 0.06
0.42%		 14.62 16.87 9.44 0.42 0.78 5.37
JDHIY
JD Health International Inc		 -
-%		 5.28 62.50 35.97 0.30 2.32 3.90

Profile*

Compass Pathways Plc

COMPASS Pathways plc operates as a biotechnology company that focuses on mental health in the United Kingdom and the United States. The company develops COMP360, a psilocybin therapy, which is in Phase III clinical trial for the treatment of treatment-resistant depression; and is in Phase II clinical trial for treating post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. The company was incorporated in 2020 and is headquartered in London, the United Kingdom.

33 Broadwick Street, London, United Kingdom, W1F 0DQ

44 716 6766461

https://compasspathways.com

156

Name Title Year Born
Mr. George Jay Goldsmith Exec. Chairman & Co-Founder 1954
Dr. Ekaterina Malievskaia M.D. Co-Founder, Chief Innovation Officer & Exec. Director 1967
Dr. Guy Goodwin Chief Medical Officer NA
Mr. Kabir Nath M.A., M.B.A. Chief Exec. Officer NA
Mr. Michael F. Falvey Chief Financial Officer 1959
Dr. Greg Ryslik Ph.D. Exec. VP of AI, Engineering, Digital Health Research & Technology NA
Mr. Stephen D. Schultz Sr. VP of Investor Relations NA
Mr. Matthew Owens Gen. Counsel & Chief Legal Officer NA
Mr. Christopher Williams Chief Communications Officer NA
Ms. Anne Benedict Chief People Officer NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

ITH
CAD 2.15
+27.68%
HG
CAD 4.11
+19.13%
PPTA
CAD 27.74
+17.99%
UCU
CAD 2.10
+17.32%
GAU
CAD 3.49
+16.72%
TSU
CAD 29.67
-29.71%
PXT
CAD 19.73
-16.91%
LAS-A
CAD 230.50
-9.25%
IFP
CAD 13.50
-8.35%
NFI
CAD 24.01
-7.80%

Equity Sectors*

  • Basic Materials

    +3.74%

  • Communication Services

    +0.56%

  • Consumer Cyclical

    -0.34%

  • Consumer Defensive

    +0.11%

  • Energy

    +1.33%

  • Financial Services

    -0.26%

  • Healthcare

    +2.54%

  • Industrials

    -0.11%

  • Real Estate

    -0.23%

  • Technology

    +1.91%

  • Utilities

    +1.05%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…